Neoantigen Peptide Vaccine

Phase 1Vaccine

TThe First Affiliated Hospital of Nanchang University

Neoantigen Peptide Vaccine is one of 68 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Preclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Imjudo

AstraZeneca

Preclinical

5 3

Gilotrif

Boehringer Ingelheim

Preclinical

12 4

Ofev

Boehringer Ingelheim

Preclinical

7 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 9

Neoantigen Peptide Vaccine

TThe First Affiliated Hospital of Nanchang University

Phase 1

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Anatomic Stage III Breast Cancer AJCC V8

NCT05269381

Q4 2028

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT05098210

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT05098210·25 enrolled

Pancreatic Cancer1 trial

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Terminated·WWashington University School of Medicine·Phase 1·NCT03956056·12 enrolled

Advanced Malignant Solid Tumors1 trial

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Recruiting·TThe First Affiliated Hospital of Nanchang University·N/A·NCT05749627·20 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Recruiting·MMayo Clinic·Preclinical·NCT05269381·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Neoantigen Peptide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoantigen Peptide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoantigen Peptide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Nanchang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital of Nanchang University

Neoantigen Peptide Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Pancreatic Cancer1 trial

Advanced Malignant Solid Tumors1 trial

Anatomic Stage III Breast Cancer AJCC v81 trial

References

Drug Info

Quick Facts

Related News